Evidence map›Paper›PMID 39938011›Full record

ArticleBlood advances2025

Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma.

Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D Shaughnessy, Fenghuang Zhan, Eric R Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Endless possibilities and how to exploit them? What is the optimal treatment sequence?Hematology. American Society of Hematology. Education Program · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bhavesh Mohan LalDepartment of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR.
Marah AlzubiDepartment of Internal Medicine, University of Jordan, Amman, Jordan.ORCID 0000-0002-0531-918X
Jawad AlrawabdehDepartment of Internal Medicine, University of Jordan, Amman, Jordan.
John D ShaughnessyDepartment of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.
Fenghuang ZhanDepartment of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.ORCID 0000-0001-5417-2973
Eric R SiegelDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR.ORCID 0000-0001-9824-6612
Carolina SchinkeDepartment of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.ORCID 0000-0002-2699-1741
Sharmilan ThanendrarajanDepartment of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.
Maurizio ZangariDepartment of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.
Frits van RheeDepartment of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.
Samer Al HadidiDepartment of Hematology and Oncology, Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39938011
PMCPMC12051553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.